Dana-Farber Cancer Institute and Mass General Hospital — Boston, Massachusetts

Dana-Farber Cancer Institute and Mass General Hospital is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 60/100 (FAIR). This profile has not yet been claimed by the site owner.

Dana-Farber Cancer Institute and Mass General Hospital has participated in 2 clinical trials.

Therapeutic areas: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma.

Sponsors: Celldex Therapeutics.

Sponsor Feasibility Report

Trust Score: 60/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana-Farber Cancer Institute and Mass General Hospital?

Dana-Farber Cancer Institute and Mass General Hospital has a Crixeo Trust Score of 60/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana-Farber Cancer Institute and Mass General Hospital conducted?

Dana-Farber Cancer Institute and Mass General Hospital has 2 clinical trials on record. Their work covers Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma.

Is Dana-Farber Cancer Institute and Mass General Hospital accredited by Crixeo Health?

Dana-Farber Cancer Institute and Mass General Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana-Farber Cancer Institute and Mass General Hospital?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.